Citizens JMP Raises PT on ABIVAX Societe Anonyme (ABVX) Stock

ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 25, Citizens JMP lifted the price target on the company’s stock to $114 from $95, while keeping an “Outperform” rating, as reported by The Fly. This announcement follows ABIVAX Société Anonyme (NASDAQ:ABVX) stating that results from the Obefazimod Phase 3 induction trials would be presented next month. As per the firm, the Phase 3 results can reinforce the strength of Obefazimod’s efficacy and increase conviction in the multi-billion-dollar sales potential.

ABIVAX Société Anonyme (NASDAQ:ABVX)’s operating loss rose by EUR 13.7 million to EUR -93.7 million for the 6 months to June 30, 2025, compared to EUR -80.0 million for the same period of the previous year. Operating income, consisting mainly of Research Tax Credit and Subsidies, fell by EUR 4.7 million to EUR 2.1 million for 6 months to June 30, 2025, as compared to EUR 6.8 million for 6 months ending June 30, 2024. The rise in operating loss was due to the operating expenses.

While we acknowledge the potential of ABVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None. This article is originally published at Insider Monkey.